Bioxyne【BXN】銘柄情報

Bioxyne Ltd (BXN) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

0.089

( 3.49% )

買値

0.086

売値

0.092

出来高

2,523,270

0.085 日の範囲 0.089

0.025 52 週間の範囲 0.095

時価総額

202.083M

前日終値

0.086

始値

0.086

時刻

0.086

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

AUD 4,109,380

発行済株式数

2,270,594,310

配当利回り

PER

21.67

1 株当たり利益 (EPS)

歳入

47.95M

純利益

8.97M

Bioxyne Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czechia, Switzerland, France, Germany, and Japan. It operates through Pharmaceutical Manufacture and Wholesale Supply... Bioxyne Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czechia, Switzerland, France, Germany, and Japan. It operates through Pharmaceutical Manufacture and Wholesale Supply of Novel Medicines, Cannabis, Psilocybin, and MDMA; Manufacture and Distribution (Wholesale, Online, and Retail) of Consumer Health and Novel Food Products; and Wholesale of Patented Probiotics segments. The company offers active pharmaceutical ingredients and starting materials; plant-based food products, such as non-controlled cannabis extracts and cannabidiol; food grade mushroom extracts/psilocybin; medicinal and prescription cannabis products, including pastilles, vape, oral mucosal oils, flower, and suppositories; SL-NAD+ wafers; MDMA; white label manufactured wellness products; health and wellness supplements; and nootropic and skincare products. It also provides Lactobacillus fermentum VRI-003 PCC, a probiotic formulation for gastrointestinal health and immunity; Progastrim for gut and immune health; and proTract for atopic dermatitis. In addition, the company is involved in the contract manufacturing of final dose form products, including capsules, tablets, inhalables, oral solutions, and herbal preparations; import, export, manufacture, and supply of controlled drugs and medicinal products; research and development of formulations, products, and processes related to health, wellness, and medicine; and provision of telemedicine services. Further, it operates CanXChange, a machine-learning powered B2B wholesale and custody technology platform. The company offers its products to cultivators, manufacturers, pharmacies, clinics, and patients under the Breathe Life Science, Dr Watson, Mirai Solution, and Apothecary CBD brands. It sells its products through wholesale, retail, and online. Bioxyne Limited is headquartered in Sydney, Australia. 詳細を表示

セクター

Consumer Staples

業界

Consumer Products - Foods

ウェブサイト

bioxyne.com

本社

Sydney, Australia

設立

Bioxyne Ltd is listed in the Consumer Staples sector of the オーストラリア証券取引所 with ticker BXN. The last closing price for Bioxyne was AUD0.09. Over the last year, Bioxyne shares have traded in a share price range of AUD 0.025 to AUD 0.095.

Bioxyne currently has 2,270,594,310 shares in issue. The market capitalisation of Bioxyne is AUD202.08 million. Bioxyne has a price to earnings ratio (PE ratio) of 21.67.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.011	14.1025641026	0.078	0.095	0.078	5681516	0.08843259	DE
4	0.006	7.22891566265	0.083	0.095	0.066	4368061	0.08065742	DE
12	0.041	85.4166666667	0.048	0.095	0.045	4410904	0.07188037	DE
26	0.051	134.210526316	0.038	0.095	0.036	3573643	0.06202187	DE
52	0.063	242.307692308	0.026	0.095	0.025	3943130	0.050742	DE
156	0.066	286.956521739	0.023	0.095	0.004	2616830	0.03729758	DE
260	0.064	256	0.025	0.095	0.004	1836613	0.03670301	DE